A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

@article{Jacobs2016AP0,
  title={A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine},
  author={Bart A. W. Jacobs and Jelte Meulenaar and Hilde Rosing and Dick Pluim and Matthijs M. Tibben and Niels de Vries and Bastiaan Nuijen and Alwin D. R. Huitema and Jos H. Beijnen and Jan H. M. Schellens and Serena Marchetti},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2016},
  volume={77},
  pages={1201-1207}
}
To examine the pharmacokinetic (PK) profile of several candidate extended-release (ER) formulations of capecitabine in patients. In a phase 0 clinical study, PK profiles of several oral candidate ER formulations of capecitabine were compared to the PK profile of capecitabine after administration of the commercially available immediate-release (IR) tablet. A… CONTINUE READING